Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.
News|Articles|June 26, 2026
FDA updates in pediatric care: Q2 2026 recap
Author(s)Morgan Ebert, Executive Editor
Fact checked by: Benjamin P. Saylor
A look back at the FDA approvals, label expansions, and regulatory decisions in the pediatric health care space from April through June 2026.
Advertisement
Advertisement
Spring gave way to summer, and along the way the FDA kept up a brisk pace of approvals, label expansions, and regulatory updates affecting pediatric patients.
Related to this article
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
Diana F. Clarke, PharmD, explains how IMPAACT 2023 supported dolutegravir from birth, plus dosing tips and open questions for preterm infants.
New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
Advertisement
Advertisement